William Blair Investment Management LLC Makes New Investment in Halozyme Therapeutics, Inc. $HALO

William Blair Investment Management LLC purchased a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 2,511,050 shares of the biopharmaceutical company’s stock, valued at approximately $196,540,000.

Several other large investors have also recently bought and sold shares of the business. EP Wealth Advisors LLC acquired a new stake in Halozyme Therapeutics in the second quarter valued at $686,000. Allworth Financial LP purchased a new position in shares of Halozyme Therapeutics in the 2nd quarter valued at about $2,948,000. Silvant Capital Management LLC acquired a new stake in shares of Halozyme Therapeutics in the second quarter valued at about $56,000. PCM Encore LLC purchased a new stake in Halozyme Therapeutics during the second quarter worth about $256,000. Finally, Vise Technologies Inc. purchased a new stake in Halozyme Therapeutics during the second quarter worth about $743,000. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Trading Up 1.9%

Halozyme Therapeutics stock opened at $108.17 on Friday. The stock has a market cap of $12.28 billion, a PE ratio of 32.29, a P/E/G ratio of 0.43 and a beta of 0.85. The stock has a 50-day moving average price of $83.19 and a 200 day moving average price of $73.74. Halozyme Therapeutics, Inc. has a 52 week low of $61.22 and a 52 week high of $108.49. The company has a current ratio of 2.71, a quick ratio of 2.31 and a debt-to-equity ratio of 13.50.

Halozyme Therapeutics (NASDAQ:HALO) last released its earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.79 by $0.49. The company had revenue of $481.00 million for the quarter, compared to analyst estimates of $402.28 million. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The firm’s quarterly revenue was up 47.7% on a year-over-year basis. During the same period in the prior year, the firm earned $1.54 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. Equities research analysts predict that Halozyme Therapeutics, Inc. will post 7.77 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Bernadette Connaughton sold 1,626 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $102.80, for a total transaction of $167,152.80. Following the transaction, the director owned 40,418 shares of the company’s stock, valued at approximately $4,154,970.40. This represents a 3.87% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mahesh Krishnan sold 7,304 shares of the firm’s stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $75.00, for a total transaction of $547,800.00. Following the sale, the director owned 14,462 shares in the company, valued at approximately $1,084,650. This trade represents a 33.56% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 64,103 shares of company stock valued at $5,226,496 over the last 90 days. Insiders own 2.50% of the company’s stock.

Analysts Set New Price Targets

HALO has been the subject of a number of research reports. Wall Street Zen upgraded shares of Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 8th. Wells Fargo & Company increased their price objective on shares of Halozyme Therapeutics from $75.00 to $95.00 and gave the company an “equal weight” rating in a research note on Friday, August 7th. Weiss Ratings cut shares of Halozyme Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research report on Friday, August 14th. Morgan Stanley reduced their price target on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating on the stock in a report on Tuesday, May 12th. Finally, HC Wainwright raised their price objective on shares of Halozyme Therapeutics from $95.00 to $115.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. Nine equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Halozyme Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $91.20.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.